Literature DB >> 3124939

Comparison of the acute effect of the intranasal and intramuscular administration of salmon calcitonin in Paget's disease.

D González1, E Vega, G Ghiringhelli, C Mautalen.   

Abstract

On 7 patients with mild-to-moderately active Paget's disease, 200 IU of salmon calcitonin (SCT) nasal spray (NS), induced a significant decrease of the total urinary hydroxyproline excretion (THP) during the 8-16 hour and the 0-24 hour (P less than 0.05) periods after treatment as compared to control day. However, the administration of 100 IU of SCT intramuscularly (i.m.) caused a significantly greater effect than 200 IU-NS during the second 8 hour period after its administration (P less than 0.01) and on the over-all 24 hour effect (P less than 0.05). On 3 patients with severe Paget's disease, SCT-NS was essentially ineffective whereas the injection of SCT induced a marked diminution of the THP excretion.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3124939     DOI: 10.1007/bf02556668

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  4 in total

1.  Side effects of synthetic salmon calcitonin given by intranasal spray compared with intramuscular injection.

Authors:  J Y Reginster; P Franchimont
Journal:  Clin Exp Rheumatol       Date:  1985 Apr-Jun       Impact factor: 4.473

2.  Modifications of a specific assay for hydroxyproline in urine.

Authors:  K I Kivirikko; O Laitinen; D J Prockop
Journal:  Anal Biochem       Date:  1967-05       Impact factor: 3.365

3.  Acute antiosteoclastic effect of salmon calcitonin in osteoporotic women.

Authors:  D González; G Ghiringhelli; C Mautalen
Journal:  Calcif Tissue Int       Date:  1986-02       Impact factor: 4.333

4.  Salmon-calcitonin nasal spray in Paget's disease of bone: preliminary results in five patients.

Authors:  J Y Reginster; A Albert; P Franchimont
Journal:  Calcif Tissue Int       Date:  1985-12       Impact factor: 4.333

  4 in total
  3 in total

Review 1.  Advances in the management of Paget's disease of bone.

Authors:  D J Hosking
Journal:  Drugs       Date:  1990-12       Impact factor: 9.546

2.  Acute effects of nasal salmon calcitonin on calcium and bone metabolism.

Authors:  G Thamsborg; S G Skousgaard; H Daugaard; S Schifter; G Kollerup; O H Sørensen
Journal:  Calcif Tissue Int       Date:  1993-10       Impact factor: 4.333

Review 3.  Intranasal salmon calcitonin. A review of its pharmacological properties and potential utility in metabolic bone disorders associated with aging.

Authors:  S P Clissold; A Fitton; P Chrisp
Journal:  Drugs Aging       Date:  1991 Sep-Oct       Impact factor: 3.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.